Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GALNT10 and IL-5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| GALNT10 Antigen | GALNT10 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed. |
View GALNT10 Products |
| IL-5 Antigen | IL-5 Recombinant Protein (Active Homodimer) High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native glycosylation. |
View IL5 Products |
| Gene Delivery | GALNT10 / IL-5 Promise-ORF / Lentivirus Full-length ORF for stable cell line development and target overexpression. |
View GALNT10 Products |
| Benchmark Ab | Anti-IL-5 Recombinant Antibody (Mepolizumab / Reslizumab Biosimilar) Recombinant positive control for binding and neutralization assays. |
View IL5 Products |
| Validator | GALNT10 / IL-5 siRNA Set For knockdown verification in functional cell-based assays. |
View GALNT10 Products |
| Related Target A | IL-5RA (Interleukin 5 Receptor Subunit Alpha) Direct receptor for IL-5. Crucial for competitive binding and receptor-blocking antibody assays. |
View IL5RA Products |
| Related Target B | GALNT1 (Polypeptide N-acetylgalactosaminyltransferase 1) Family homolog for specificity and off-target screening in glycan-modifying therapeutic programs. |
View GALNT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GALNT10 enzymatic specificity & off-target screening | High-purity GALNT family homolog proteins (GALNT1, GALNT2, GALNT10) strictly verified by mass spectrometry. |
| IL-5 active homodimer conformation preservation | HEK293 expressed recombinant IL-5 with native disulfide-linked homodimeric structure and mammalian glycosylation. |
| Lack of clinical benchmark controls | In-house synthesized clinical benchmark antibodies (Mepolizumab/Reslizumab sequence-verified biosimilars) included |
| False positive results in functional screening | Sequence-verified siRNA sets included for target-specific knockdown validation |
Live GALNT10 & IL-5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active IL-5 Clinical Trials
- ➤ Latest GALNT10 Oncology Research
- ➤ Recent GALNT10 Patent Filings
Global Clinical Landscape & Future Outlook
The therapeutic targeting of IL-5 is highly mature in the respiratory space, with established blockbusters like mepolizumab and reslizumab demonstrating profound clinical efficacy in severe eosinophilic asthma. The next wave of R&D is focused on long-acting formulations, subcutaneous (Sub-Q) high-concentration delivery, and multi-specific biologics targeting synergistic cytokine pathways (such as IL-4/IL-13/IL-5 bispecifics).
In contrast, GALNT10 represents an emerging frontier in oncology. As an initiator of O-linked glycosylation, GALNT10 is overexpressed in various solid tumors (e.g., ovarian, breast, and gastric cancers) and is heavily implicated in tumor immune evasion and metastasis. Current research is rapidly shifting toward the development of selective small-molecule inhibitors, antibody-drug conjugates (ADCs) targeting tumor-specific glyco-epitopes, and therapeutic antibodies designed to disrupt GALNT10-mediated immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (IL-5) | GSK, Teva, AstraZeneca | Severe Eosinophilic Asthma, EGPA | Neutralization Assay (Requires HEK293-expressed, fully glycosylated active IL-5 homodimer) |
| Bispecific / Multi-specific (IL-5/IL-x) | Sanofi, Roche | Type 2 Inflammatory Diseases | Simultaneous binding kinetics (Requires high-purity IL-5 and IL-5RA monomeric/dimeric proteins) |
| Small Molecule Inhibitors (GALNT10) | Academic Institutes, Biotech Startups | Ovarian Cancer, Immunotherapy Resistance | Enzymatic activity assays (Requires highly pure, sequence-verified active GALNT10 recombinant enzymes) |
| ADC / Glyco-targeting mAbs (GALNT10) | Oncology-focused Biotechs | Solid Tumors (Breast, Gastric) | Internalization validation (Requires cell line construction via GALNT10 Lentiviral transduction) |